Refractory thrombocytopenia due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation

Case report and review of literature

Vivek Roy, C. M. Verfaillie

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A 43-year-old woman developed life-threatening refractory thrombocytopenia following autologous peripheral blood stem cell transplantation for metastatic breast carcinoma. Anti-PLA1 antibodies were demonstrated in the patient's plasma. Treatment with intravenous immunogiobulin and transfusion of PLA1-negative blood products restored platelet responsiveness. PLA1 alloantibodies should be considered as a possible cause of severe refractory thrombocytopenia in marrow transplant patients. It is important to make this diagnosis as the mainstay of treatment is the avoidance of blood products from PLA1-positive donors (98% of the population).

Original languageEnglish (US)
Pages (from-to)115-117
Number of pages3
JournalBone Marrow Transplantation
Volume17
Issue number1
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
Thrombocytopenia
Anti-Idiotypic Antibodies
Isoantibodies
Blood Platelets
Bone Marrow
Tissue Donors
Breast Neoplasms
Transplants
Therapeutics
Population

Keywords

  • Anti-PL antibodies
  • Peripheral blood stem cells
  • Thrombocytopenia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{73b673b422974593bf6dc839eb030e51,
title = "Refractory thrombocytopenia due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation: Case report and review of literature",
abstract = "A 43-year-old woman developed life-threatening refractory thrombocytopenia following autologous peripheral blood stem cell transplantation for metastatic breast carcinoma. Anti-PLA1 antibodies were demonstrated in the patient's plasma. Treatment with intravenous immunogiobulin and transfusion of PLA1-negative blood products restored platelet responsiveness. PLA1 alloantibodies should be considered as a possible cause of severe refractory thrombocytopenia in marrow transplant patients. It is important to make this diagnosis as the mainstay of treatment is the avoidance of blood products from PLA1-positive donors (98{\%} of the population).",
keywords = "Anti-PL antibodies, Peripheral blood stem cells, Thrombocytopenia",
author = "Vivek Roy and Verfaillie, {C. M.}",
year = "1996",
month = "1",
day = "1",
language = "English (US)",
volume = "17",
pages = "115--117",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Refractory thrombocytopenia due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation

T2 - Case report and review of literature

AU - Roy, Vivek

AU - Verfaillie, C. M.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - A 43-year-old woman developed life-threatening refractory thrombocytopenia following autologous peripheral blood stem cell transplantation for metastatic breast carcinoma. Anti-PLA1 antibodies were demonstrated in the patient's plasma. Treatment with intravenous immunogiobulin and transfusion of PLA1-negative blood products restored platelet responsiveness. PLA1 alloantibodies should be considered as a possible cause of severe refractory thrombocytopenia in marrow transplant patients. It is important to make this diagnosis as the mainstay of treatment is the avoidance of blood products from PLA1-positive donors (98% of the population).

AB - A 43-year-old woman developed life-threatening refractory thrombocytopenia following autologous peripheral blood stem cell transplantation for metastatic breast carcinoma. Anti-PLA1 antibodies were demonstrated in the patient's plasma. Treatment with intravenous immunogiobulin and transfusion of PLA1-negative blood products restored platelet responsiveness. PLA1 alloantibodies should be considered as a possible cause of severe refractory thrombocytopenia in marrow transplant patients. It is important to make this diagnosis as the mainstay of treatment is the avoidance of blood products from PLA1-positive donors (98% of the population).

KW - Anti-PL antibodies

KW - Peripheral blood stem cells

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0030071802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030071802&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 115

EP - 117

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -